80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]鄭妮冰 陳 斌 彭麗云.PCSK9基因rs662145位點(diǎn)多態(tài)性與冠狀動(dòng)脈粥樣硬化性心臟病血脂的關(guān)系[J].福建醫(yī)藥雜志,2020,42(04):1-5.
　ZHENG Nibing,CHEN Bin,PENG Liyun..Relationship between rs662145 polymorphism of PCSK9 gene and blood lipid in patients with coronary atherosclerotic heart disease[J].FUJIAN MEDICAL JOURNAL,2020,42(04):1-5.
點(diǎn)擊復(fù)制

PCSK9基因rs662145位點(diǎn)多態(tài)性與冠狀動(dòng)脈粥樣硬化性心臟病血脂的關(guān)系()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
42
期數(shù):
2020年04期
頁碼:
1-5
欄目:
臨床研究
出版日期:
2020-08-20

文章信息/Info

Title:
Relationship between rs662145 polymorphism of PCSK9 gene and blood lipid in patients with coronary atherosclerotic heart disease
文章編號(hào):
1002-2600(2020)04-0001-05
作者:
鄭妮冰 陳 斌 彭麗云
福建省立醫(yī)院心內(nèi)一科(福州 350001)
Author(s):
ZHENG Nibing; CHEN Bin; PENG Liyun.
Department of Cardiology,Fujian Provincial Hosptial,Fuzhou,Fujian 350001,China
關(guān)鍵詞:
PCSK9基因;  rs662145位點(diǎn);  冠心病;  脂代謝;  他汀
Keywords:
PCSK gene;  rs662145;  coronary heart disease;  lipid profiles;  statins
分類號(hào):
R541.4
文獻(xiàn)標(biāo)志碼:
B
摘要:
目的 探討PCSK9基因rs662145位點(diǎn)多態(tài)性與冠狀動(dòng)脈粥樣硬化性心臟病(coronary atherosclerotic heart disease,CHD)的關(guān)系,并觀察他汀在PCSK基因rs662145位點(diǎn)不同基因型中調(diào)脂效果的差異。方法 選取行CAG檢查的福建漢族患者261例,根據(jù)CAG結(jié)果分為CHD組和對照組,收集患者的基本資料并留取空腹血標(biāo)本,測定TG、TC、LDL-C等血脂指標(biāo),采用聚合酶鏈反應(yīng)-限制性片段長度多態(tài)性(PCR-RFLP)技術(shù)檢測PCSK9基因rs662145位點(diǎn)多態(tài)性,并在完成隨訪的57例患者復(fù)測相應(yīng)血脂指標(biāo)。結(jié)果 CHD組rs662145位點(diǎn)C等位基因頻率為20.59%,高于對照組的10.53%(χ2=6.011,P=0.019); CC、CT、TT基因型頻率在兩組間分布差異也有統(tǒng)計(jì)學(xué)意義(χ2=9.418,P=0.007); 含C等位基因CHD組患者TC及LDL-C水平更高(CC>CT>TT,P<0.05),但HDL-C較低(CC<0.05)。chd組患者血漿tc、hdl-c、ldl-c、apoa水平在cc、ct、tt基因型亞組間的差異有統(tǒng)計(jì)學(xué)意義(p><0.05),對照組血脂水平在各基因型亞組間的差異無統(tǒng)計(jì)學(xué)意義(p>0.05)。CHD患者經(jīng)過他汀治療后,血漿TG、TC及LDL-C水平均較前降低,HDL-C水平較前升高(P<0.05),但CC、CT、TT各基因型患者經(jīng)他汀治療前后血脂變化值差異無統(tǒng)計(jì)學(xué)意義(P>0.05)。結(jié)論 PCSK9基因rs662145位點(diǎn)多態(tài)性與福建漢族冠心病人群血脂異常有關(guān),rs662145位點(diǎn)C等位基因可能是冠心病高風(fēng)險(xiǎn)突變位點(diǎn)。/html>
Abstract:
Objective To explore the relationship between rs662145 polymorphism of PCSK9 gene and blood lipid in patients with coronary atherosclerotic heart disease,and to compare the efficacy of statins in various PCSK9 rs662145 genotypes in patients with coronary atheroscleroticheart disease.Methods A total of 261 patients undergoing coronary angiography were divided into CHD group(n=204)and control group(n=57).Basic information,fasting glucose,total triglyceride(TG), total cholesterol(TC)and low density lipoprotein cholesterol(LDL-C)and other lipid profiles were tested immediately after admission.Genotyping of PCSK9 polymorphisms was performed using polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP)method.Lipid profile was redetermined in patients who had accepted statins for three months and completed the follow-up.Results The frequency of C allele was 20.59% in CHD group,which was higher than 10.53% in the control group(χ2=6.011,P=0.019).The distribution of PCSK9 rs662145 genotype(CC,CT,TT)among two groups showed statistically significant difference(χ2=9.418,P=0.007).Patients with C allele in CHD group had higher levels of TC and LDL-C but lower HDL-C levels(P<0.05).TC,HDL-C,LDL-C and ApoA levels also demonstrated statistically significant difference between three genotypes(CC,CT and TT)in the CHD group(P<0.05),meanwhile no difference was seen in the lipid profiles of the control group among three genotypes.TG,TC and LDL-C levels decreased with the elevation of HDL-C after three months treatment with statins in CHD group(P<0.05).No significant differences were observed in the variation of lipid profile after treatment with statins among three genotypes(CC,CT,TT)(P>0.05).Conclusion PCSK9 gene rs662145 polymorphism was associated with lipid levels in CHD patients among Fujian Han population.C allele may increase the risk of the onset of coronary heart disease.

參考文獻(xiàn)/References:

[1] 胡盛壽,高潤霖,劉力生,等.《中國心血管病報(bào)告2018》概要[J].中國循環(huán)雜志,2019,34(3):209-220.
[2] Ference Brian A,Ginsberg Henry N,Graham Ian,et al.Low-density lipoproteins cause atherosclerotic cardiovascular disease.1.Evidence from genetic, epidemiologic, and clinical studies.A consensus statement from the European Atherosclerosis Society Consensus Panel[J].Eur Heart J,2017,38(32):2459-2472.
[3] Pott J,Schlegel V,Teren A,et al.Genetic Regulation of PCSK9(Proprotein Convertase Subtilisin/Kexin Type 9)Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes[J]. Circulation Genomic & Precision Medicine,2018,11(5):e001992.
[4] Abifadel M,Varret M,Rabès J P,et al.Mutations in PCSK9 cause autosomal dominant hypercholesterolemia[J]. Nature Genetics,2003,34(2):154-156.
[5] Qiu C F,Zeng P Y,Li X H,et al.What is the impact of PCSK9rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk:a meta-analysis[J]. Lipids in Health and Disease,2017,16(1):111.
[6] Chuan J L,Qian Z X, Zhang Y,et al.The association of the PCSK9 rs562556 polymorphism with serum lipids level:A meta-analysis[J]. Lipids in health and disease,2019,18(1):105.
[7] Shibata N,Ohnuma T,Higashi S, et al.No genetic association between PCSK9 polymorphisms and Alzheimers disease and plasma cholesterol level in Japanese patients[J]. Psychiatric genetics,2005,15(4):239.
[8] 趙婷婷.PCSK9、LDLR基因多態(tài)性與生活行為因素對高脂血癥影響的研究[D].新疆:石河子大學(xué),2014.
[9] Zheng Li,Tianyu Zhao,Xiaohua Tan, et al.Polymorphisms in PCSK9, LDLR, BCMO1, SLC12A3,and KCNJ1 are Associated with Serum Lipid Profile in Chinese Han Population[J]. Int J Environ Res Public Health,2019,16(17):3207.
[10] 楊林承,祖凌云,高煒.PCSK9基因突變與冠心病[J].中國介入心臟病學(xué)雜志,2018,26(8):457-461.
[11] Feng Q,Wei W Q,Chung C P,et al.The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy[J]. Pharmacogenomics Journal,2017,17(2):204-208.
[12] 張楠,高靜,劉寅,等.PCSK9基因E670G位點(diǎn)多態(tài)性與冠狀動(dòng)脈粥樣硬化性心臟病罹病風(fēng)險(xiǎn)及脂代謝的相關(guān)性研究[J]. 中華醫(yī)學(xué)遺傳學(xué)雜志,2017,34(5):749-754.
[13] Wanmasae S,Sirintronsophon W,Porntadavity S,et al.The effect of APOE,CETP,and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients[J]. Cardiovascular Therapeutics,2017,35(6):doi: 10.1111/1755-5922.12302.

備注/Memo

備注/Memo:
基金項(xiàng)目:福建省衛(wèi)生健康科研人才培養(yǎng)項(xiàng)目醫(yī)學(xué)創(chuàng)新課題(2019-CXB-2)
更新日期/Last Update: 2020-08-20